[go: up one dir, main page]

TR200101336T2 - Combinations with a beta-agonist and another antidiabetic agent - Google Patents

Combinations with a beta-agonist and another antidiabetic agent

Info

Publication number
TR200101336T2
TR200101336T2 TR2001/01336T TR200101336T TR200101336T2 TR 200101336 T2 TR200101336 T2 TR 200101336T2 TR 2001/01336 T TR2001/01336 T TR 2001/01336T TR 200101336 T TR200101336 T TR 200101336T TR 200101336 T2 TR200101336 T2 TR 200101336T2
Authority
TR
Turkey
Prior art keywords
agonist
beta
combinations
antidiabetic agent
another antidiabetic
Prior art date
Application number
TR2001/01336T
Other languages
Turkish (tr)
Inventor
Robert Sanders Arch Jonathan
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9824790.1A external-priority patent/GB9824790D0/en
Priority claimed from GBGB9824789.3A external-priority patent/GB9824789D0/en
Priority claimed from GBGB9824791.9A external-priority patent/GB9824791D0/en
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of TR200101336T2 publication Critical patent/TR200101336T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)

Abstract

Bir memelide, örnegin bir insanda diyabet mellitusun ve diyabet mellitus ile ilgili vakalarin tedavisi için, ihtiyaç duyan memeliye bir beta antagonisti ve baska bir antidiyabetik maddeden, etkili, toksik olmayan ve farmasötik olarak kabul edilebilir bir miktarda verilmesini içeren bir yöntem.A method for the treatment of diabetes mellitus and cases related to diabetes mellitus in a mammal, for example, in a human, comprising administering to the mammal in need in an effective, non-toxic and pharmaceutically acceptable amount.

TR2001/01336T 1998-11-11 1999-11-11 Combinations with a beta-agonist and another antidiabetic agent TR200101336T2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9824790.1A GB9824790D0 (en) 1998-11-11 1998-11-11 Novel method of treatment
GBGB9824789.3A GB9824789D0 (en) 1998-11-11 1998-11-11 Novel method of treatment
GBGB9824791.9A GB9824791D0 (en) 1998-11-11 1998-11-11 Novel methods of treatment

Publications (1)

Publication Number Publication Date
TR200101336T2 true TR200101336T2 (en) 2001-11-21

Family

ID=27269550

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/01336T TR200101336T2 (en) 1998-11-11 1999-11-11 Combinations with a beta-agonist and another antidiabetic agent

Country Status (15)

Country Link
EP (1) EP1128845A1 (en)
JP (1) JP2002529430A (en)
KR (1) KR20010075698A (en)
CN (1) CN1332638A (en)
AU (1) AU766928B2 (en)
BR (1) BR9915214A (en)
CA (1) CA2350062A1 (en)
CZ (1) CZ20011655A3 (en)
HK (1) HK1041201A1 (en)
HU (1) HUP0104388A3 (en)
IL (1) IL143004A0 (en)
NO (1) NO20012300L (en)
PL (1) PL348154A1 (en)
TR (1) TR200101336T2 (en)
WO (1) WO2000027434A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ531929A (en) * 1999-12-23 2006-01-27 Novartis Ag Use of nateglinide as a hypoglycemic agent for treating impaired glucose metabolism
AU2007201729B2 (en) * 1999-12-23 2010-02-25 Novartis Ag Use of hypoglycemic agent for treating impaired glucose metabolism
WO2001047509A2 (en) * 1999-12-24 2001-07-05 Smithkline Beecham P.L.C. Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions
US20030018061A1 (en) * 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
WO2001083453A1 (en) * 2000-04-28 2001-11-08 Asahi Kasei Kabushiki Kaisha Novel substituted tricyclic compounds
AU2001252575A1 (en) * 2000-04-28 2001-11-12 Asahi Kasei Kabushiki Kaisha Novel tricyclic compounds
WO2006132196A1 (en) * 2005-06-08 2006-12-14 Asahi Kasei Pharma Corporation NOVEL PHARMACEUTICAL COMPRISING β3 AGONIST
US11053255B2 (en) 2015-06-22 2021-07-06 Georgetown University Synthesis of mahanine and related compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2059121T5 (en) * 1990-02-09 2000-12-01 Upjohn Co USE OF INSULIN SENSITIZING AGENTS TO TREAT HYPERTENSION.
ZA967892B (en) * 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
AU715233B2 (en) * 1996-01-10 2000-01-20 Asahi Kasei Kogyo Kabushiki Kaisha Novel tricyclic compounds and drug compositions containing the same

Also Published As

Publication number Publication date
PL348154A1 (en) 2002-05-06
AU766928B2 (en) 2003-10-23
CN1332638A (en) 2002-01-23
IL143004A0 (en) 2002-04-21
WO2000027434A1 (en) 2000-05-18
HUP0104388A2 (en) 2002-03-28
CA2350062A1 (en) 2000-05-18
KR20010075698A (en) 2001-08-09
NO20012300D0 (en) 2001-05-10
NO20012300L (en) 2001-07-03
BR9915214A (en) 2001-12-18
EP1128845A1 (en) 2001-09-05
HK1041201A1 (en) 2002-07-05
HUP0104388A3 (en) 2002-12-28
JP2002529430A (en) 2002-09-10
CZ20011655A3 (en) 2002-06-12
AU1063400A (en) 2000-05-29

Similar Documents

Publication Publication Date Title
TR199903057T2 (en) Treatment of diabetes with thiazolidinedione and metformin.
MXPA02012763A (en) Combinations of depeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabete mellitus.
TR200102977T2 (en) New treatment method.
YU37301A (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
IT1302307B1 (en) COMPOSITION WITH ANTIOXIDANT ACTIVITY AND FOR IMPROVING THE METABOLIC USE OF GLUCOSE, INCLUDING ACETYL
CA2023630A1 (en) Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs
BG95935A (en) METHOD AND AGENT FOR ADMINISTERING DEXMEDETOMIDINE DIRECTLY THROUGH THE SKIN
CA2420694A1 (en) Guanidinobenzamides as mc4-r agonists
TR200101336T2 (en) Combinations with a beta-agonist and another antidiabetic agent
TR199903095T2 (en) Treatment of diabetes with rosiglitazone and insulin.
EA200000139A1 (en) TREATMENT OF DIABETES THIAZOLIDINDIONON, MEANS, INCENTIVE INSULIN SECRETION, AND DIGUANIDE
ES2131122T3 (en) USE OF IL-10 TO PREVENT INSULIN DEPENDENT DIABETES MELLITUS.
TR200503846T2 (en) Alternative use for modified release insulin sensitiser and use
EP1621207A3 (en) Mixture of defibrotide and G-CSF, and its use for activating haematopoietic progenitors
TR199903072T2 (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase.
TR200000133T2 (en) Treatment of diabetes (diabetic) with thiazolidinedione, insulin secretagogue and alpha glucosidase inhibitor.
TR200000135T2 (en) Diabetes treatment with thiazolidinedione and sulfonylurea.
AR008025A1 (en) PHARMACEUTICAL COMBINATION OF A THIAZOLIDINDIONA AND AN INSULIN SECRETOGOGUE
FI850644A7 (en) In vitro diagnostic procedure and diagnostic agent.
NZ506406A (en) Compositions comprising Mycobacterium phlei DNA and methods for its use in the treatment of bladder cancer
TR200000957T2 (en) The use of thiazolidinedione in the treatment of hyperglycemia
WO2001047509A3 (en) Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions
TR200000958T2 (en) The use of thiazolidinedione in the treatment of hyperglycemia.
ES1011560U (en) Higienica feminine sanitary napkin. (Machine-translation by Google Translate, not legally binding)
AP1692A (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent.